Related Experiment Video

Updated: May 2, 2026

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

9.8K

Multidrug-resistant breast cancer: current perspectives

Heather L Martin1, Laura Smith2, Darren C Tomlinson1

  • 1BioScreening Technology Group, Leeds Institutes of Molecular Medicine, University of Leeds, Leeds, UK.

Breast Cancer (Dove Medical Press)
|March 21, 2014
PubMed

Insights

Multidrug-resistant breast cancer poses a clinical challenge. Understanding molecular mechanisms like the phosphatidylinositide 3-kinase/Akt pathway, microRNAs, and epigenetics can lead to new targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is a leading global cancer in women.
  • Therapeutic resistance is a significant clinical hurdle.
  • Understanding resistance mechanisms is crucial for developing novel treatments.

Purpose of the Study:

  • To review recent advances in understanding multidrug-resistant breast cancer.
  • To emphasize common molecular mechanisms underlying resistance to targeted and chemotherapies.
  • To discuss the interaction of these mechanisms and potential therapeutic targets.

Main Methods:

  • Literature review of recent advances in breast cancer resistance.
  • Focus on molecular mechanisms including phosphatidylinositide 3-kinase/Akt pathway, microRNAs, and epigenetic alterations.
  • Discussion of therapeutic strategies targeting these resistance mechanisms.

Main Results:

  • Identified key molecular mechanisms contributing to multidrug resistance in breast cancer.
  • Highlighted the interplay between the phosphatidylinositide 3-kinase/Akt pathway, microRNAs, and epigenetic changes.
  • Explored how these mechanisms confer resistance to tamoxifen, trastuzumab, and chemotherapies.

Conclusions:

  • Understanding molecular mechanisms of resistance is vital for overcoming therapeutic challenges in breast cancer.
  • Targeting pathways like PI3K/Akt, microRNAs, and epigenetic modifications offers potential for new treatment strategies.
  • Combined targeting of these mechanisms may improve efficacy against multidrug-resistant breast cancer.
Keywords:
ERHER2PI3K/AktepigeneticsmiRNAtriple negative

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K
Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

1.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
90
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K